KHK6640 Phase1 study (A Phase1 Randomized, Placebo-Controlled, Double-Blind, Repeated Dose Study of KHK6640 in Japanese Patients with Alzheimer's Disease)
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2018
At a glance
- Drugs KHK 6640 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin
- 19 Mar 2018 Status changed from active, no longer recruiting to completed.
- 03 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 30 Mar 2017 Status changed from not yet recruiting to recruiting.